SCHEMBL13289334

SCHEMBL13289334

Bc1cnn2c(NCc3cccc(NC(=O)Nc4ccccc4C)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 5/20 0.49
▸ GSK3B P49841 5/20 0.49
▸ DDX3X O00571 2/20 0.42
▸ AURKA O14965 1/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ EPHB4 P54760 2/20 0.39
▸ ITGB1 P05556 1/20 0.39
▸ ITGA4 P13612 1/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ PTGER3 P43115 2/20 0.38
▸ IMPDH2 P12268 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ HCRTR1 O43613 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289563 0.92 CDK2 (0.50) CDK2GSK3BAURKARPS6KB1AURKB
SCHEMBL13121739 0.91 CDK2 (0.61) CDK2GSK3B
SCHEMBL13289245 0.91 CDK2 (0.49) CDK2GSK3BAURKAAURKBEPHB4
SCHEMBL13289700 0.91 CDK2 (0.47) CDK2GSK3BAURKAPDPK1RPS6KB1
SCHEMBL13289254 0.90 CDK2 (0.47) CDK2GSK3BAURKARPS6KB1AURKB
SCHEMBL12954468 0.90 CDK2 (0.51) CDK2GSK3BAURKAPDPK1RPS6KB1
SCHEMBL14301776 0.90 CDK2 (0.51) CDK2GSK3BAURKARPS6KB1AURKB
SCHEMBL13289340 0.88 CDK2 (0.48) CDK2GSK3BPTGER3
SCHEMBL13289304 0.88 CDK2 (0.48) CDK2GSK3BAURKAPDPK1RPS6KB1
SCHEMBL12954205 0.88 CDK2 (0.49) CDK2GSK3BAURKAPDPK1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback